Should Not Children with Ventriculoatrial Shunts Be Taking Aspirin? An Update: 0% Distal Malfunction

Area of Science:

• Pediatric Neurosurgery
• Cardiovascular Complications
• Medical Device Management

Background:

• Ventriculoatrial (VA) shunts are life-preserving alternatives to ventriculoperitoneal (VP) shunts but carry risks of cardiac complications.
• Current guidelines lack specific protocols for screening, anticoagulation, and risk management in patients with VA shunts.
• Distal thrombosis is a significant concern leading to secondary morbidity in VA shunt recipients.

Purpose of the Study:

• To evaluate the efficacy of aspirin in improving shunt survival rates in pediatric patients with VA shunts.
• To assess aspirin's role in preventing cardiac complications and distal thrombosis associated with VA shunts.
• To investigate the safety profile of aspirin as an antiplatelet agent in this patient population.

Main Methods:

• Prospective, observational study initiated in 2011, with ongoing patient follow-up.
• Inclusion criteria involved obtaining hospital ethics board approval and family consent.
• All pediatric patients received a daily dose of 5 mg/kg aspirin from the first postoperative day.

Main Results:

• Thirteen patients have been followed since March 2011, with follow-up durations ranging from 28 to 170 months.
• No cardiac complications directly attributed to the VA shunts have been observed in the study cohort to date.
• Patient follow-up is ongoing, with continued monitoring for shunt-related adverse events.

Conclusions:

• Preliminary findings suggest aspirin is a safe and potentially effective adjunctive therapy for VA shunts in children.
• The encouraging safety and efficacy data warrant further investigation into long-term outcomes.
• Longer follow-up periods are necessary to definitively establish aspirin's role in preventing chronic sequelae like pulmonary hypertension.